[{"id":"9e19f934-321f-4e6c-b066-71f0217f0bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03041688","created_at":"2021-01-18T14:58:33.453Z","updated_at":"2025-02-25T12:26:38.524Z","phase":"Phase 1","brief_title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03041688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-24"},{"id":"593b542b-470d-465e-ae6a-8f9b079a6849","acronym":"ALLIANCE-ABTC-1604","url":"https://clinicaltrials.gov/study/NCT03107780","created_at":"2021-01-18T15:18:36.892Z","updated_at":"2025-02-25T13:48:22.462Z","phase":"Phase 1","brief_title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","source_id_and_acronym":"NCT03107780 - ALLIANCE-ABTC-1604","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 03/21/2019","primary_completion_date":" 03/21/2019","study_txt":" Completion: 02/07/2026","study_completion_date":" 02/07/2026","last_update_posted":"2025-02-21"},{"id":"c26f7e4c-301c-4f7a-9c9b-fcbebe86dda6","acronym":"NRG-DT001","url":"https://clinicaltrials.gov/study/NCT03217266","created_at":"2021-01-18T15:52:30.675Z","updated_at":"2024-07-02T16:35:02.993Z","phase":"Phase 1","brief_title":"Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma","source_id_and_acronym":"NCT03217266 - NRG-DT001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MDM2 • MDM4 • CD4","pipe":"","alterations":" ","tags":["TP53 • MDM2 • MDM4 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 08/27/2023","primary_completion_date":" 08/27/2023","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-17"},{"id":"2d84bdc7-c6f6-41e1-b766-7bba4beee15a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03031730","created_at":"2021-01-18T14:55:20.440Z","updated_at":"2024-07-02T16:35:14.475Z","phase":"Phase 1","brief_title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","source_id_and_acronym":"NCT03031730","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone • navtemadlin (KRT-232) • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/14/2018","start_date":" 06/14/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-15"},{"id":"f29dab42-3218-4cee-9ccf-b710607d907c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669067","created_at":"2021-01-19T20:44:14.797Z","updated_at":"2024-07-02T16:35:55.237Z","phase":"Phase 1b/2","brief_title":"TL-895 and KRT-232 Study in Acute Myeloid Leukemia","source_id_and_acronym":"NCT04669067","lead_sponsor":"Telios Pharma, Inc.","biomarkers":" TP53 • FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation • TP53 wild-type","tags":["TP53 • FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232) • TL895"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-02-17"},{"id":"7581583e-6318-4ab9-9ba7-a352be1b7dec","acronym":"KRT-232-117","url":"https://clinicaltrials.gov/study/NCT04835584","created_at":"2022-04-24T09:03:04.624Z","updated_at":"2024-07-02T16:36:15.052Z","phase":"Phase 1b/2","brief_title":"KRT-232 and TKI Study in Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04835584 - KRT-232-117","lead_sponsor":"Kartos Therapeutics, Inc.","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" TP53 wild-type","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • nilotinib • navtemadlin (KRT-232)"],"overall_status":"Recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/07/2021","start_date":" 05/07/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2022-03-21"}]